Saudi market index closes

TASI
10,326.47
+18.10 (+0.18%)
MT30
1,400.46
+2.64 (+0.19%)
NOMU (Capped)
22,054.14
+105.57 (+0.48%)
Sukuk
890.39
-0.62 (-0.07%)

Source: Saudi Exchange data supplied for this session. Not live prices.

GoFinsa

Welcome to GoFinsa!

SULAIMAN ALHABIB

4013

GoFinsa Saudi Stock Investment Strength Index

59%
Investment strength
Explore the GoFinsa Saudi Stocks Index →

Analytical index, not a guaranteed return or buy recommendation.

213.6 SAR
Change: +0.7 SARChange %: +0.33 %Trading volume: 380,157 sharesTrades: 3,177 Open: 213 SARHigh: 214.5 SARLow: 212.1 SAR
Last available trade from session · 2026-11-12

SULAIMAN ALHABIB stock (4013) price and technical analysis

GoFinsa tracks SULAIMAN ALHABIB under symbol 4013, with the latest available price at 213.6 SAR. This page includes multi-timeframe charts, technical analysis and related market news.

Market data source: بيانات جلسة السوق السعودي المقدمة من المستخدم · Latest available update: 2026-11-12 · Delayed market data

Dr. Sulaiman Al Habib Stock (4013): Price, GoFinsa Rating and News

GoFinsa provides a guide to Dr. Sulaiman Al Habib stock, listed under ticker 4013, including its economic sector and factors that may help readers assess the stock.

About Dr. Sulaiman Al Habib and the Company's Activities

Dr. Sulaiman Al Habib (ticker 4013) operates in the Saudi market and is described as manufacturing or distributing pharmaceutical preparations. The company description also lists hospitals, healthcare, pharmacies and pharmaceutical products among its areas of activity. This summary describes the stated business areas; it does not mean that all of them contribute equally to revenue or that any particular financial results have been achieved.

Dr. Sulaiman Al Habib Stock Information

Dr. Sulaiman Al Habib stock trades on the Saudi Exchange under ticker 4013 and belongs to the healthcare sector. Reviewing official disclosures and financial results can help readers understand the company's position and how its business develops.

Company Activities and Information

The company is classified in the healthcare sector of the Saudi market. Annual reports and official disclosures should be consulted to understand its activities, revenue sources and operational developments.

The Healthcare Sector in the Saudi Economy

The performance of listed healthcare companies can be affected by demand for their products and services, operating costs, competition, and economic and regulatory conditions. Each company's sensitivity to these factors depends on its business model.

How to Read the Stock's Financial Results

It is important to compare revenue, profit, cash flow and debt across several financial periods, and to understand the reasons for changes rather than relying on the result for a single quarter. Official announcements should also be reviewed for information about material events.

Factors That May Affect the Stock's Price

Dr. Sulaiman Al Habib stock may be affected by the company's results and disclosures, trends in the Saudi market, interest rates and investor expectations. A change in the share price alone does not indicate an improvement in operating performance.

Investment Risks

Potential risks include share-price volatility, changes in costs, weaker demand, competition and regulatory changes. Actual risks vary according to the company's activities and financial position.

Stock Strength According to the GoFinsa Saudi Stocks Index

The rating recorded for the stock in the GoFinsa GFSI is 61%. This is an independent analytical rating, not a guarantee of profit or a personal recommendation to buy.

Investing in Saudi Stocks

The Saudi Exchange includes companies operating across a range of economic sectors. Investors can benefit from reviewing disclosures, comparing financial valuations, diversifying risk and setting an investment time horizon before making a decision.

Following Company News

The latest disclosures and news concerning Dr. Sulaiman Al Habib stock can be followed through news sources and official data available on GoFinsa. Readers should note the date of each item and how directly it relates to the company.

Dr. Sulaiman Al Habib Reference Price

The recorded reference price is SAR 228.7, dated 2026-10-08. This is a historical price, not a live quote or a confirmed current trading price.

Dr. Sulaiman Al Habib Rating in the GoFinsa GFSI

The stock's rating in the GoFinsa GFSI is 61%. This is a GoFinsa research rating, not a recommendation to buy or sell.

About the Healthcare Sector

Dr. Sulaiman Al Habib stock belongs to the healthcare sector on the Saudi Exchange. Companies in the sector may be affected by demand, competition, costs, and economic and regulatory conditions. Their revenue sources and risk profiles differ.

Trading Through XTB and Associated Risks

What Does Dr. Sulaiman Al Habib Do?

Dr. Sulaiman Al Habib (4013) belongs to the healthcare sector. The candidate business scope identified for research includes operating hospitals and medical centers and providing treatment services. Specific details and subsidiary activities should be checked against the company's latest official profile before publication.

Where Does Dr. Sulaiman Al Habib's Revenue Come From?

When analyzing Dr. Sulaiman Al Habib's business model, review the following potential sources of income to the extent supported by the company's financial statements: revenue from medical services, visit volumes, occupancy and case mix. Their inclusion here does not establish that each item contributes to the company's actual revenue.

Factors That May Affect Dr. Sulaiman Al Habib's Performance

Relevant operating indicators to monitor for Dr. Sulaiman Al Habib include occupancy rates, expansion, staffing costs and contracts with insurance companies. Trends should be compared across multiple periods using the company's actual results. Growth or profitability should not be inferred without documented figures.

What to Check in the Annual Disclosure

When researching Dr. Sulaiman Al Habib (4013), first identify the date of the latest annual report. Then review the description of actual activities, operating segments and revenue recognition policy. Read the notes to the financial statements rather than relying only on management's summary, as the notes may disclose obligations or events that are not apparent from headline figures. Confirm the identity of the listed entity, its subsidiaries and the nature of their operations before attributing any activity or project to the company. Trends in the healthcare sector should not be treated as evidence of revenue growth at this company unless supported by its published results.

How to Distinguish Real Growth from Accounting Changes

To analyze Dr. Sulaiman Al Habib, compare results for several equivalent periods and watch for non-recurring items, reclassifications and changes in the consolidation scope. Higher revenue does not necessarily mean improved profitability if the cost of sales or expenses have risen faster. Review operating and net profit margins, then consult management's explanations for the changes in the financial statement notes. If reliable, up-to-date financial statements are unavailable, these remain analytical steps rather than a description of the company's actual performance.

Cash Flow and the Ability to Fund Operations

When reviewing Dr. Sulaiman Al Habib's financial data, it is useful to distinguish accounting profit from cash generated by operations. Examine net operating cash flow, changes in working capital, capital expenditure and financing costs. A company can report a profit while operating cash declines because of higher receivables, inventory or project payments. Conversely, cash flow may be temporarily affected by the timing of collections and payments. The company's liquidity or solvency cannot be assessed without the relevant financial statements and notes.

Debt and Financing Costs: Key Questions

If Dr. Sulaiman Al Habib has financing obligations, begin by identifying maturities, the split between short- and long-term debt, borrowing costs and any contractual covenants. Assess how changes in interest rates could affect earnings and cash flows, taking into account whether financing instruments have fixed or variable rates. The relevance of these questions depends on the company's healthcare business model. This guide does not assume that the company has any particular level of debt or risk.

Comparing the Stock with Sector Peers Without Misleading Conclusions

For a fair comparison of Dr. Sulaiman Al Habib stock, select companies with similar activities, revenue mix, scale and regulatory environments. Compare revenue growth, margins, return on capital and cash flow, and then account for differences in accounting and leverage. A lower price-to-earnings multiple than that of another company is not, by itself, enough to conclude that the stock is cheaper; the difference may reflect expectations for growth, risk or earnings quality. If a company has losses or non-recurring profits, some valuation multiples may not be suitable for comparison.

How to Read the Reference Price and Its Date

The reference price shown in this guide is historical and dated; it is not a live bid or offer. When assessing Dr. Sulaiman Al Habib, check which trading session the price relates to and whether any capital changes, stock splits or distributions could affect historical comparisons. Do not confuse the previous closing price with the latest trade or the average price during a session. If market data updates are delayed, the date should be shown clearly, and an old figure should not be used to infer a new daily trend.

Build Scenarios Rather Than Predicting a Specific Price

Three scenarios can be used to study Dr. Sulaiman Al Habib: improving business conditions, conditions remaining broadly unchanged, and a decline in demand or margins. For each scenario, define measurable assumptions such as sales volume, input costs or financing expenses, then compare the results with published financial statements when available. Do not set a price target without a valuation model and documented inputs, and do not present the positive scenario as an expected outcome. This approach is intended to show how an investment may respond to new information.

Checklist Before Making an Investment Decision

Before dealing in Dr. Sulaiman Al Habib stock, confirm ticker 4013, the company's identity and the price date. Read the latest material disclosure, financial results and auditor's notes, if any. Distinguish GoFinsa's research rating from whether the investment is suitable for your personal circumstances. Set an investment horizon, consider your tolerance for loss and review your portfolio's exposure to the healthcare sector. Also check broker fees and the type of financial instrument: owning shares directly differs from trading derivatives or contracts for difference, which may involve additional risks.

أسئلة شائعة عن الشركة

What is Dr. Sulaiman Al Habib's stock ticker?

The stock trades on the Saudi Exchange under ticker 4013.

Which sector does Dr. Sulaiman Al Habib stock belong to?

The stock belongs to the healthcare sector.

Is the GoFinsa rating a buy recommendation?

No. The rating is an analytical tool and is not a personal investment recommendation or a guarantee of future performance.

Frequently asked questions about SULAIMAN ALHABIB (4013)

What is the price of SULAIMAN ALHABIB (4013)?

The latest price available in GoFinsa data is 213.6 SAR. Price status may be live or delayed depending on the market and data provider.

What does the technical analysis for SULAIMAN ALHABIB (4013) show?

There is currently insufficient data to produce technical analysis for this instrument.

What is the GoFinsa.com General Index for SULAIMAN ALHABIB?

The GoFinsa.com General Index is currently unavailable for this instrument.